Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 327 followers
Latest posts
Last updated 1 day ago
Windtree offloads cardio pipeline, Vaccinex secures $60M funding in continued holiday shopping spree
1 day ago
Windtree Therapeutics has not been shy about its desire to become a...
Tela Bio sues BD over hernia mesh monopoly claims
1 day ago
The rival maker of hernia mesh implants claimed the major medtech used...
Edwards nets FDA approval for Sapien M3 transcatheter mitral valve replacement
1 day ago
The approval marks the first for a type of implant that takes...
The top 5 stock picks for biotech in 2026: William Blair
1 day ago
William Blair has hand-picked its top five stock recommendations for 2026, selections...
Hope springs toward Parkinson's phase 3 despite divergent stem cell therapy data
1 day ago
Hope Biosciences has linked its stem cell therapy candidate to improved motor...
Despite geopolitical pressures, China biotech deals remain at pace as collective value soars: Evaluate
1 day ago
Despite a year of trade tensions, national security strictures and stark warnings...
Miracle babies, antibiotic improv and T-cell tamers: Fierce's favorite research stories of 2025
1 day ago
It was the best of times and it was the worst of...
6 people charged in $41M insider trading scheme tied to 2 biotechs
2 days ago
Six people, including a former employee of investment bank Citigroup’s San Francisco...
Abbott’s Volt pulsed field ablation system scores FDA approval
2 days ago
With the U.S. green light, Abbott’s newcomer will compete with hardware with...
BioMarin quietly discards liver disease candidate after $4.8B Amicus announcement
2 days ago
Amid news of the splashy $4.8 billion Amicus buy, BioMarin has slipped...
Editor's corner: Fierce Medtech's top 10 stories of 2025 show how tech can treat
2 days ago
One main thread in our most-read stories of 2025 is that new...
Gilead pays $35M to license pair of HSV assets from Assembly Bio pact
2 days ago
Two years after Gilead secured the first option on Assembly Biosciences’ entire...